Brief: Avidity Biosciences Announces Positive Aoc 1044 Data Demonstrated Significant Increase Of 25% In Dystrophin Production And Reduction Of Creatine Kinase Levels To Near Normal In People Living With Duchenne Muscular Dystrophy Amenable To Exon 44 Skipping In The Phase 1/2 Explore44™ Trial

Avidity Biosciences

09/08/2024 12:05

Aug 9 (Reuters) - Avidity Biosciences Inc  RNA.O :
    * AVIDITY BIOSCIENCES ANNOUNCES POSITIVE AOC 1044 DATA
DEMONSTRATED SIGNIFICANT INCREASE OF 25% IN DYSTROPHIN
PRODUCTION AND REDUCTION OF CREATINE KINASE LEVELS TO NEAR
NORMAL IN PEOPLE LIVING WITH DUCHENNE MUSCULAR DYSTROPHY
AMENABLE TO EXON 44 SKIPPING IN THE PHASE 1/2 EXPLORE44™ TRIAL
    * AVIDITY BIOSCIENCES INC - DELPACIBART ZOTADIRSEN DATA
DEMONSTRATED FAVORABLE SAFETY AND TOLERABILITY

Source text for Eikon:  ID:nPn7B6SCxa 
Further company coverage:  RNA.O 

 ((Reuters.Briefs@thomsonreuters.com;))